Frovatriptan Succinate Tablet Market

Key data points: Market size in 2027 = $1.3 billion and 2035 = $1.5 billion, growth forecast = 3.5% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in frovatriptan succinate tablet market to 2035 by type (original drug and generic drug), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Frovatriptan Succinate Tablet Market The future of the global frovatriptan succinate tablet market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global frovatriptan succinate tablet market is expected to reach an estimated $1.5 billion by 2035 from $1.3 billion in 2027 with a CAGR of 3.5% from 2027 to 2035. The major drivers for this market are the increasing prevalence of migraine headaches, the rising demand for affordable migraine medications, and the growing awareness of targeted headache therapies. • Lucintel forecasts that, within the type category, generic drug is expected to witness higher growth over the forecast period due to more affordable generic drugs. • Within the application category, retail pharmacies is expected to witness higher growth over the forecast period due to more retail pharmacy sales of migraine medications. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more retail pharmacies and more people with migraine. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Frovatriptan Succinate Tablet Market Frovatriptan tablets will see growing demand during 2025 to 2027 as more oral, targeted and affordable therapies for migraine become available. What drives demand in the future will be how generic versions of the drug become available, how well the drug is prescribed, how well the drug is accepted by patients and how convenient it is to find the drug in pharmacies. According to Lucintel, the migraine market is large and still offers opportunities for growth for new migraine drugs. The points given below describe possible opportunities and challenges for the frovatriptan market. Opportunities: • Generalizing or ‘genericizing’: Although the U.S. version of Frova is no longer available, other suppliers of the generic version of Frova continue to be available. During this time, the price of the drug will come down. • Patient Centered Dosing: Frovatriptan is different from other triptans, in that it has a longer half-life, therefore, it would be a better choice to treat migraine attacks associated with the menstrual cycle. • Preventive Care: Incorporating CGRP therapies in preventive care does not mean that other acute migraine therapies will be completely replaced. Therefore, in the next few years, it is expected that frovatriptan will be used in combination with other therapies to prevent and treat migraines. • Evidence-led Segmentation: We expect clinical and real-world studies up to 2025 to leverage the timing of migraine attacks in relation to the menstrual cycle, migraine recurrence, and the presence of CV risk factors to define and characterize migraine populations. Positive formulary listings and prescribing decisions for frovatriptan will occur 3-5 years after the publication of these studies. Consequently, a higher priority will be placed on positions and populations where the pharmacology of frovatriptan will be most beneficial. • Supply Resilience: There have been substantial disruptions in the pharmaceutical supply and drug shortages in recent years. As a result, greater emphasis has been placed by pharmaceutical buyers to ensure there is more than one supplier for a given pharmaceutical, as well as assurance of regulatory and GMP compliance by the supplier of Active Pharmaceutical Ingredients. From 2025 to 2027, manufacturers that provide most assurances of ongoing supply of the pharmaceutical and support documentation will be awarded contracts, even at constrained prices. Recent Developments in the Frovatriptan Succinate Tablet Market Lucintel predicts minor growth for frovatriptan succinate tablets between 2023-2027, due to rising demand for migraine treatments and price-eroding generic competition. During this period, supplier and manufacturing strategies will be complemented by prescription practices based on clinical evidence. • Rising Generic Competition: As of January 2025, several manufacturers will be largely price-Generic for 2.5 mg frovatriptan tablets. During this environment, branded companies will be rewarded by the migration of loyal customers to the best quality and economics (i.e. batch) of the product. • Limits on Labeling: The FDA has limited the labeling for frovatriptan to 2.5 mg, twice daily for the preventative treatment of migraines associated with menstruation. While this type of labeling facilitates prescription for migraine prevention, it limits the product to this specific indications. • Contract Manufacturing: Dual sourcing and supplier qualification by generic manufacturers has increased for 2025 and beyond, due to lingering Pharmaceutical ingredient concentration concerns. • Portfolio Substitution: Newer CGRP-based medicines have and will continue to interrupt the migraine treatment landscape. The American Headache Society (AHS) considers CGRP therapies as the first line of migraine prevention. While the AHS recommendation will increasingly position frovatriptan as a therapy of last resort, frovatriptan’s low cost and current acceptance in the migraine market will ensure frovatriptan will remain a treatment option for patients. • Evidence Based-practice for Menstrual Migraine: Separating menstrual migraine from common migraine allows for the use of time-restricted triptans (2025). This will protect the current market for triptans, however continued usage and reliance on triptans will depend on diagnosis rates and compliance. The future of frovatriptan will be determined by multiple factors such as the availability of raw materials, manufacturing and pharmacy considerations. Preserving current position in the market will depend on the ability of pharmaceutical companies to allow frovatriptan to be used only in cases where it is medicinally justified. Strategic Growth Opportunities in the Frovatriptan Succinate Tablet Market The frovatriptan succinate tablet market is evolving because of evolving migraine diagnostics and diThanks for uploading this preview of your document. You will find more useful tools when you download the latest version of MS Word. Check out the five-year outlook (2024-2026) that includes the rising preference for generic migraine medications. Lucintel’s market intelligence offers insights into other growth opportunities and forms of revenue beyond conventional Drug Channels. • Adolescent Migraine: The American Migraine Foundation noted in June 2025 that migraine affects 10% of children. Thus, there is potential to capture a new, albeit small, patient population. • Women’s Health: The International Classification of Headache Disorders states that globally, 15% of women are affected by migraine. If pharmaceutical companies position their products to treat menstrual migraine, they have the potential to capture a new patient population. • Digital Prescribing and Pharmacy Access: In January 2025, the U.S. telehealth market explored new digital routes to serve millions of virtual consultations. Pharmacists extended their scope to access patient records and prescribe and/or dispense medication. • Emerging Market Potential: In April 2025, data from the International Headache Society reported migraine prevalence to be 14% globally. With strategic localizations and joint ventures in the next five years, migraine medications have the potential to capture unmet consumer needs. • Adherence Packaging: In February 2025, the FDA label for frovatriptan continued to restrict the prescribing dose to 2.5 mg. From a commercial standpoint, all pharmaceutical products become commodities. Calendar packaging, along with patient instruction and support, help differentiate products. The migraine market will continue to grow in the next five years, and the most successful manufacturers will be those that expand frovatriptan’s market presence through differentiated pharmacy products and support, target untapped markets, and extend market accessibility and economics through pharmacists. Both manufacturers and payers agree the best way to achieve adherence in the migraine market is through product differentiation; therefore, the next several years will be dominated by evidenced-based product launches. Frovatriptan Succinate Tablet Market Drivers and Challenges Frovatriptan succinate tablet market growth is shaped by patient demand, pharmaceutical innovation, healthcare access, pricing, and safety regulation. Oral triptan therapy remains relevant for acute migraine management because of its convenient administration and long duration of action. However, generic competition, contraindications, diagnostic complexity, and newer migraine treatments create pressure. Lucintel analysis indicates that market performance will depend on balancing affordability, clinical effectiveness, regulatory compliance, and differentiation over the next three to five years. The factors responsible for driving the frovatriptan succinate tablet market include:- • Patient Demand: Recurrent migraine prevalence and demand for convenient self-administered treatments support continued use of oral frovatriptan. The standard tablet strength is 2.5 mg, reinforcing simple dosing and portability (January 2025). Persistent treatment needs will sustain demand, especially among patients seeking longer-lasting relief. • Long Duration of Action: Frovatriptan’s comparatively long half-life can help address migraine recurrence and reduce the need for repeated dosing. Its labeled maximum daily dose is 7.5 mg (February 2025), supporting predictable treatment planning. Over the next three to five years, this advantage may preserve its role among patients prioritizing durable symptom control. • Generic Cost Advantages: Generic availability can lower treatment costs for patients, insurers, and healthcare systems. A 2.5 mg generic tablet remains the principal marketed strength in many channels (March 2025). As payers emphasize cost containment, affordable generic options will help maintain prescription volume despite competition from newer branded therapies. • E-Prescribing and Pharmacy Access: Wider electronic prescribing, mail-order services, and retail pharmacy availability improve access to acute migraine medicines. Digital prescription platforms commonly support 24-hour refill workflows (April 2025), reducing treatment delays. Over the next three to five years, improved distribution and telehealth integration will expand access for patients with recurring migraine episodes. • Product and Treatment Innovation: Combination therapies, improved patient education, and migraine-focused care pathways can increase appropriate use of established medicines such as frovatriptan. Clinical guidelines continue distinguishing acute treatment from preventive therapy (May 2025). Better diagnosis and individualized prescribing will support demand where frovatriptan’s pharmacological profile matches patient needs. The challenges facing this Market include: • Cardiovascular Safety Restrictions: Triptans, including frovatriptan, are not suitable for patients with certain cardiovascular conditions, limiting the eligible population. Product labeling identifies contraindications such as coronary artery disease and uncontrolled hypertension (January 2025). These restrictions will continue influencing prescribing decisions and encourage clinicians to consider non-triptan alternatives for higher-risk patients. • Competition from Newer Therapies: Gepants, ditans, injectables, and preventive biologics provide additional choices for migraine treatment. At least three major non-triptan acute therapy classes are available by 2025 (June 2025). Their differentiated safety or convenience profiles may reduce frovatriptan growth, particularly among patients who experience inadequate response or contraindications. • Generic Pricing and Supply Pressure: Price competition can reduce manufacturer margins, while procurement disruptions may affect pharmacy availability. A single 2.5 mg strength limits product-line flexibility compared with broader dosage portfolios (July 2025). Over the next three to five years, suppliers will need efficient manufacturing, dependable distribution, and regulatory compliance to protect market continuity. The frovatriptan succinate tablet market will remain supported by recurring migraine prevalence, oral convenience, long duration of action, generic affordability, and expanding healthcare access. Nevertheless, cardiovascular restrictions, strong competition from newer therapies, and pricing or supply pressures will constrain expansion. Market participants that maintain reliable availability, demonstrate cost effectiveness, and support appropriate patient selection will be better positioned. Overall, the market is likely to experience steady, specialized demand rather than rapid growth, with clinical suitability and affordability determining long-term performance. List of Frovatriptan Succinate Tablet Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies frovatriptan succinate tablet market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the frovatriptan succinate tablet market companies profiled in this report include- • Endo International • Menarini • Ingenus Pharmaceutical • Glenmark Pharmaceuticals • SK Chemicals Frovatriptan Succinate Tablet Market by Segment The study includes a forecast for the global frovatriptan succinate tablet market by type, application, and region. Frovatriptan Succinate Tablet Market by Type [Value ($B) from 2019 to 2035]: • Original Drug • Generic Drug Frovatriptan Succinate Tablet Market by Application [Value ($B) from 2019 to 2035]: • Hospital & Clinic • Retail Pharmacies • Others Frovatriptan Succinate Tablet Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Frovatriptan Succinate Tablet Market The frovatriptan succinate tablet market is dominated by established migraine treatment markets. Around 2025 to 2027, companies are expected to focus on balancing and optimizing their product offerings. In Lucintel’s most recent report, they noted that in 2025, regulatory bodies would play the largest role in the market. • United States: Competing companies focus on marketing and selling generic versions of frovatriptan succinate. In the 2.5 mg strength, frovatriptan succinate tablets are available. The Drug Approval Package for 2025, published by the Food and Drug Administration (FDA) showed no frovatriptan approvals. Over the next 3-5 years, it is expected that market access would be determined by a company’s negotiation with health care organizations and plans for reimbursement. • China: The National Medical Products Administration (NMPA) focused on the assessment of pharmaceutical products for quality and generic medicines in 2025. Frovatriptan is not on China’s National Reimbursement Drug List. Given the lack of reimbursement, it is unlikely that frovatriptan would be widely prescribed. Changes in the pharmaceutical market would depend on the outcomes of government contracts and tenders. • Germany: Germany followed its AMNOG and reference price processes for 2025 for prescription migraine medicines. The statutory health insurance contribution rate for 2025 was 14.6%, excluding the supplementary contribution. We found no evidence of the launch of new frovatriptan tablets in Germany for the period analyzed. Thus, in the absence of premium product regional or national launches, we anticipate more generic product substitution and supply chain dynamics would drive market growth. • India: In 2025, India’s Central Drugs Standard Control Organisation (CDSCO) continued to control the licensing process for all schedule H (oral) prescription drugs. Large pharmaceutical companies had to adhere to the revised Schedule M from December 28, 2023, while smaller companies had additional time. How long Indian pharmaceutical companies can maintain the necessary controls to manufacture quality medicines for international markets will impact the number of new product registrations. • Japan: As of June 2025, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan had not approved frovatriptan tablets. Other migraine medicines have been launched in Japan, and frovatriptan is of little interest to pharmaceutical companies in Japan. Thus, it is unlikely that frovatriptan will be launched in Japan in the near term. Features of the Global Frovatriptan Succinate Tablet Market Market Size Estimates: frovatriptan succinate tablet market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: frovatriptan succinate tablet market size by type, application, and region in terms of value ($B). Regional Analysis: frovatriptan succinate tablet market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the frovatriptan succinate tablet market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the frovatriptan succinate tablet market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the frovatriptan succinate tablet market by type (original drug and generic drug), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?